Tumour and patient factors in renal cell carcinoma-towards personalized therapy (Q38418649)

2 September 2017

1 reference

title

Tumour and patient factors in renal cell carcinoma-towards personalized therapy (English)

1 reference

2 September 2017

Ahmed Q Haddad

1

1 reference

2 September 2017

Vitaly Margulis

series ordinal

2

1 reference

2 September 2017

language of work or name

English

0 references

publication date

14 April 2015

1 reference

2 September 2017

published in

Nature Reviews Urology

1 reference

2 September 2017

volume

12

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

253-262

1 reference

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Comprehensive molecular characterization of clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Integrated molecular analysis of clear-cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Variation in genomic landscape of clear cell renal cell carcinoma across Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

The somatic genomic landscape of chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Renal cell cancer stage migration: analysis of the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Evaluation and management of the renal mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Resistance to targeted therapy in renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Molecular genetics of clear-cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

The genetic basis of kidney cancer: a metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

The multifaceted von Hippel-Lindau tumour suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

VHL loss causes spindle misorientation and chromosome instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Epigenetics of Kidney Cancer And Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

A Specific Gene Expression Signature Characterizes Metastatic Potential in Clear Cell Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Gene expression profiling predicts survival in conventional renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

The causes and consequences of genetic heterogeneity in cancer evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

The clonal evolution of tumor cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Cancer heterogeneity: implications for targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Clonal selection drives genetic divergence of metastatic medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Tumour evolution inferred by single-cell sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Clonal evolution in breast cancer revealed by single nucleus genome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

A molecular classification of papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Inherited susceptibility to uterine leiomyomas and renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Influence of tumour micro-environment heterogeneity on therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Apolipoprotein E/C1 locus variants modify renal cell carcinoma risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Germline genetic variations at 11q13 and 12p11 locus modulate age at onset for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Putting tumours in context

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Immune modulation for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Tumor-associated macrophages: from mechanisms to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Tumor-associated macrophages as major players in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Autocrine CSF-1 and CSF-1 Receptor Coexpression Promotes Renal Cell Carcinoma Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Sorafenib induces autophagy and suppresses activation of human macrophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Expansion of myeloid immune suppressor Gr CD11b cells in tumor-bearing host directly promotes tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Multi-institutional validation of a new renal cancer-specific survival nomogram

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Improved prognostication of renal cell carcinoma using an integrated staging system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Immunotherapy for advanced renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Overall survival in renal-cell carcinoma with pazopanib versus sunitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Renal cell cancer histological subtype distribution differs by race and sex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Gene signatures of progression and metastasis in renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases--an analysis by comparative genomic hybridization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2015.71

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

31 March 2020

1 reference

12 December 2020

Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma

1 reference

12 December 2020

Surveillance strategies for renal cell carcinoma patients following nephrectomy.

1 reference

12 December 2020

Hereditary papillary renal cell carcinoma

1 reference

12 December 2020

Racial difference in histologic subtype of renal cell carcinoma

1 reference

12 December 2020

An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score

1 reference

12 December 2020

Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases

1 reference

12 December 2020

Genetic alterations in primary bladder cancers and their metastases.

1 reference

12 December 2020

Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2015.71

1 reference

Dimensions Publication ID

2 September 2017

1037473809

0 references

1 reference